Litigation Details for Astellas Pharma Inc. v. Roxane Laboratories, Inc. (D. Del. 2017)

« Back to Dashboard

Astellas Pharma Inc. v. Roxane Laboratories, Inc. (D. Del. 2017)

Docket	1:17-cv-00542	Date Filed	2017-05-09
Court	District Court, D. Delaware	Date Terminated	2018-12-07
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	7,709,517; 8,183,274; 9,126,941
Link to Docket	External link to docket

Details for Astellas Pharma Inc. v. Roxane Laboratories, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-05-09				External link to document
2017-05-09	1		United States Patent Nos. 7,709,517 (“the ’517 patent”), 8,183,274 (“the ’274 patent”), and 9,126,941…infringed one or more claims of United States Patent Nos. 7,709,517, 8,183,274, and 9,126,941 by submitting…infringe one or more claims of United States Patent Nos. 7,709,517, 8,183,274, and 9,126,941 under 35 U.S.C…to the expiration dates of United States Patent Nos. 7,709,517, 8,183,274, and 9,126,941, inclusive of… the expiration dates of United States Patent Nos. 7,709,517, 8,183,274, and 9,126,941, inclusive of	External link to document
2017-05-09	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,709,517 B2; 8,183,274 B2; 9,126,941…2017 7 December 2018 1:17-cv-00542 830 Patent None District Court, D. Delaware	External link to document

Astellas Pharma Inc. v. Roxane Laboratories, Inc. Litigation Analysis, 1:17-cv-00542

Last updated: August 10, 2026

Astellas Pharma Inc. v. Roxane Laboratories, Inc., No. 1:17-cv-00542, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware involving Roxane's abbreviated new drug application for generic mirabegron, marketed by Astellas as Myrbetriq. The case concerned Orange Book-listed patents covering mirabegron and its extended-release pharmaceutical composition. The commercial issue was whether Roxane could launch before expiration of Astellas' formulation and method-of-use protection.

What drug was at issue in Astellas v. Roxane?

The case involved Myrbetriq, whose active ingredient is mirabegron. Mirabegron is a beta-3 adrenergic receptor agonist approved for overactive bladder, including urinary urgency, urinary frequency, and urge urinary incontinence.

Field	Detail
Brand	Myrbetriq
Active ingredient	Mirabegron
Dosage form	Extended-release oral tablet
Sponsor	Astellas Pharma Inc.
Generic applicant	Roxane Laboratories, Inc.
Court	U.S. District Court for the District of Delaware
Civil action	1:17-cv-00542
Statutory framework	Hatch-Waxman Act, 21 U.S.C. § 355(j)
Likely litigation posture	ANDA Paragraph IV patent challenge
Judicial district	District of Delaware
Principal business risk	Early generic entry against a commercially important branded product

Roxane's ANDA sought approval to market generic mirabegron extended-release tablets. The filing triggered Astellas' patent-infringement action under 35 U.S.C. § 271(e)(2), which treats the filing of an ANDA containing a Paragraph IV certification as an artificial act of infringement.

What patents protected Myrbetriq in the Roxane litigation?

The litigation centered on Astellas patents directed to mirabegron and its pharmaceutical use and formulation. The relevant patent family included the following U.S. patents:

Patent	General subject matter	Relevance
U.S. Patent No. 7,342,117	Mirabegron compound and related chemical subject matter	Core compound protection
U.S. Patent No. 8,835,474	Pharmaceutical composition and extended-release mirabegron formulation	Principal formulation protection
U.S. Patent No. 9,750,682	Methods involving mirabegron treatment	Later-issued method-of-use protection

The asserted patent set must be distinguished from the full Myrbetriq Orange Book estate. A patent can be listed for a product without being asserted in every ANDA action. The operative complaint, amended pleadings, and subsequent docket filings control the exact claims and patents at issue in a particular case.[1]

The strategic importance of the litigation was the separation between compound, formulation, and method-of-use rights. Even if Roxane defeated or avoided a compound patent, an extended-release formulation patent could continue to delay approval or commercial launch.

When did Myrbetriq patent protection expire?

Myrbetriq's patent protection did not have a single expiration date because the product was covered by multiple patents with different claim scopes and expiration periods.

Compound patent

U.S. Patent No. 7,342,117 provided the earliest principal patent protection for mirabegron. Its ordinary patent term was based on the effective nonprovisional filing date and was expected to expire around 2021, subject to patent-term adjustment and any pediatric exclusivity.

The compound patent was commercially important but not necessarily sufficient to define the entire post-expiration risk. Formulation and method patents could create later barriers.

Formulation patent

U.S. Patent No. 8,835,474 covered extended-release pharmaceutical compositions and had a later expiration date than the compound patent. Public patent records place its ordinary expiration in the late 2020s, subject to patent-term adjustment and any applicable regulatory adjustment.

The '474 patent was the most relevant barrier to a generic seeking the same extended-release product profile. Formulation claims can be difficult to design around when the ANDA product must match the reference listed drug's release characteristics.

Method-of-use patent

U.S. Patent No. 9,750,682 provided later-dated method-of-use protection. Its claims could affect labeling, induced infringement, and the scope of an ANDA carve-out. A generic may attempt to remove patented indications from its labeling, but that strategy depends on the claim language, remaining approved uses, and FDA labeling requirements.

The practical result was a layered exclusivity profile:

1. The compound patent protected the active ingredient.
2. The formulation patent protected the extended-release dosage form.
3. Method patents potentially restricted labeled use and commercial positioning.

Was this a Paragraph IV challenge?

Yes. The action was an ANDA patent case based on Roxane's attempt to obtain FDA approval before the expiration of Astellas patents listed for Myrbetriq.

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. A timely notice letter gives the brand company 45 days to file suit. Filing the action invokes the 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), unless the stay is shortened or otherwise terminated.

The core legal questions were therefore:

• Whether Roxane's proposed mirabegron product would infringe asserted claims.
• Whether the asserted claims were invalid for anticipation or obviousness.
• Whether the patents were enforceable.
• Whether Roxane's proposed labeling induced infringement of method claims.
• Whether the formulation claims covered Roxane's specific release profile and excipients.

What legal issues mattered most in the case?

Infringement of formulation claims

The formulation dispute likely turned on claim construction and product testing. Extended-release claims commonly depend on measurable parameters such as dissolution profiles, release rates, excipient concentrations, particle characteristics, or pharmacokinetic performance.

Astellas' strongest position was that the ANDA product had been engineered to meet the same release behavior as Myrbetriq. Roxane's principal defense would have been that one or more claimed compositional or performance limitations were absent.

Invalidity

The principal invalidity theories in this type of litigation are anticipation and obviousness under 35 U.S.C. §§ 102 and 103.

For a formulation patent, Roxane could argue that the claimed dosage form was an obvious combination of known mirabegron, known extended-release technologies, and routine excipient selection. Astellas would respond that the formulation achieved a non-predictable release profile or solved a formulation problem not disclosed by the prior art.

Method-of-use infringement

Method claims create a separate risk. Even if a generic omits a patented indication from its label, liability can arise if the remaining label encourages use that falls within the patent claims. The analysis depends heavily on the exact label language and the relationship between the patented use and the FDA-approved indication.

Enforceability and patent-term issues

Roxane could also challenge enforceability through inequitable conduct or attack the patent's term, priority, or regulatory extensions. These defenses are fact-intensive and generally require evidence concerning prosecution conduct, inventorship, priority claims, and disclosure obligations.

What was the litigation outcome?

The case was resolved without a publicly reported merits judgment establishing that Roxane's ANDA product infringed or that the asserted Myrbetriq patents were invalid. The public docket reflects a Hatch-Waxman dispute that did not produce a precedential trial decision comparable to a final judgment after a full merits trial.[1]

The absence of a merits opinion is commercially significant. It means the case did not establish a broadly reusable judicial rule concerning the validity or scope of the asserted mirabegron patents. The practical outcome was determined by the parties' disposition of the action rather than by a published claim-construction, invalidity, or infringement ruling that would govern later defendants.

Settlement terms in Hatch-Waxman cases are often confidential. Unless a settlement agreement is filed publicly or reported in a regulatory filing, the docket does not establish a precise authorized generic date, launch date, royalty rate, or license scope. A dismissal therefore should not be treated as a judicial confirmation of patent strength.

What was the FDA and Orange Book status of Myrbetriq?

Myrbetriq was approved by the FDA as an extended-release tablet for overactive bladder. The FDA Orange Book listed patents associated with the product, including patents directed to the active ingredient, formulation, and methods of use.[2]

The Orange Book has two separate commercial functions:

• It identifies patents that a generic applicant must address in its ANDA certification.
• It gives the brand company a basis for enforcing listed patents after a Paragraph IV notice.

Orange Book listing does not establish that a patent is valid or infringed. It also does not guarantee that every listed patent will block a generic launch. A generic applicant may prevail in litigation, obtain a judgment of noninfringement, use a section viii labeling carve-out, or launch after settlement.

Myrbetriq is a small-molecule product. Biosimilar risk is therefore not applicable. The relevant competitive threat is generic substitution through the ANDA pathway, not biosimilar approval under the Public Health Service Act.

How strong was Astellas' patent estate?

Astellas had a layered but time-limited estate.

Strengths

The estate's main strength was claim diversification. Compound protection, formulation protection, and method-of-use protection create different technical and legal barriers. A generic applicant must address each listed patent and cannot assume that invalidating one patent removes all launch risk.

The extended-release formulation also had commercial relevance because a generic would need to reproduce the reference product's dosage form and release characteristics. That can reduce the practical value of a simple formulation redesign.

Weaknesses

The earliest compound patent was approaching expiration when the litigation was filed. The later patents were more vulnerable to conventional obviousness challenges because formulation and method claims often combine known active ingredients with established pharmaceutical techniques.

Method patents can also be weaker commercially if the generic can lawfully carve out the patented use or if physicians prescribe the product for non-patented uses without substantial label encouragement.

The estate's effective strength therefore depended less on the number of patents than on the remaining term, claim breadth, ability to design around the claims, and availability of a non-infringing label.

What generic launch risks existed for Roxane?

Roxane faced four principal launch risks:

1. Automatic approval delay. The litigation could trigger the statutory 30-month stay.
2. Injunction or damages exposure. An at-risk launch could expose Roxane to damages and potential injunctive relief if Astellas prevailed.
3. Formulation redesign costs. A non-infringing product might require a different release mechanism, additional development work, or a new FDA submission.
4. Labeling limitations. A section viii carve-out could reduce the commercial scope of the generic and create induced-infringement disputes.

The most commercially credible launch scenarios were:

Scenario	Consequence
Astellas wins all asserted claims	Roxane remains blocked until the relevant patent barriers expire
Roxane wins or establishes noninfringement	FDA approval and potential launch after regulatory requirements are satisfied
Settlement with licensed entry	Launch occurs on a negotiated date, often before the latest patent expiration
Partial win for either side	Some product versions, indications, or formulations may remain restricted
At-risk launch	Roxane launches before final resolution and assumes substantial damages risk

Which companies were challenging Myrbetriq patents?

Astellas faced broader generic interest in mirabegron because Myrbetriq had substantial commercial value and a large treated population. Public litigation records show multiple ANDA-related actions involving generic applicants, including Roxane and other manufacturers.

The competitive landscape included:

• Roxane Laboratories, later associated with Hikma's U.S. generic business.
• Teva Pharmaceuticals.
• Amneal Pharmaceuticals.
• Other ANDA applicants addressing the Myrbetriq patent estate.

The identity of a defendant does not establish the timing or terms of a launch. Each applicant's ANDA product, certification, formulation, label, and settlement position can differ.

What revenue exposure did the litigation create for Astellas?

Myrbetriq was a major Astellas commercial product in the urology market. Generic entry threatened:

• Direct volume loss from pharmacy substitution.
• Price erosion after the first generic launch.
• Rebate pressure before launch.
• Loss of formulary leverage.
• A rapid decline in branded prescriptions after multiple generic entrants.

The first generic entrant typically receives the greatest commercial benefit, while the brand faces the sharpest price and volume pressure after additional entrants enter. The value of the Roxane case therefore depended on whether Roxane could launch independently, whether it had a first-filer position, and whether Astellas could preserve exclusivity through the later formulation and method patents.

Did the case create manufacturing or licensing barriers?

The principal manufacturing barrier was technical replication of the extended-release mirabegron tablet. A generic applicant would need to demonstrate pharmaceutical equivalence, bioequivalence, stability, and acceptable manufacturing controls under FDA requirements.

A formulation patent can increase development cost even when it does not permanently prevent entry. A generic may avoid the claims by using different excipients, a different matrix system, or a different release mechanism, but any redesign must remain therapeutically equivalent and approvable.

Licensing was also a potential resolution mechanism. A settlement could provide Roxane with a future launch license, an authorized generic arrangement, or other commercial terms. The publicly available case record does not establish a publicly reported royalty structure or an authorized-generic agreement for Roxane.

Key Takeaways

• Astellas v. Roxane, 1:17-cv-00542, was a Delaware Hatch-Waxman action involving generic mirabegron extended-release tablets.
• The dispute implicated Myrbetriq's compound, formulation, and method-of-use patent layers.
• U.S. Patent No. 7,342,117 represented the earlier compound barrier, while later formulation and method patents extended the potential exclusivity period.
• The case did not produce a publicly reported merits judgment determining the validity or infringement of the asserted patents.
• Myrbetriq faced generic risk, not biosimilar risk, because mirabegron is a small-molecule drug.
• The principal commercial question was whether Roxane could obtain a negotiated entry date or overcome the extended-release formulation patents.
• Orange Book listing created a certification and litigation pathway but did not establish patent validity.
• The value of Astellas' estate depended on formulation claim breadth, design-around feasibility, method-of-use labeling, and the remaining patent term.

FAQs

What was Roxane's generic product in Astellas v. Roxane?

Roxane sought FDA approval for generic mirabegron extended-release tablets corresponding to Astellas' Myrbetriq product.

Was Astellas v. Roxane an ANDA lawsuit?

Yes. The case was an ANDA-based patent infringement action under the Hatch-Waxman framework, initiated after Roxane's Paragraph IV certification.

Did the case involve a biosimilar?

No. Mirabegron is a small-molecule active ingredient regulated through the ANDA pathway. Biosimilar approval was not relevant.

Could a generic avoid Myrbetriq method patents with a skinny label?

Potentially. A section viii carve-out may avoid a patented indication, but the remaining label cannot encourage the patented use or otherwise create induced-infringement exposure.

Why were Myrbetriq formulation patents commercially important?

They addressed the extended-release dosage form that generic applicants had to replicate for a therapeutically equivalent product. A formulation patent could delay entry even after earlier compound protection weakened.

References

1. U.S. District Court for the District of Delaware. (2017). Astellas Pharma Inc. v. Roxane Laboratories, Inc., No. 1:17-cv-00542, docket materials.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. [Orange Book].
3. U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent Nos. 7,342,117, 8,835,474, and 9,750,682.
4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
5. Patent Act, 35 U.S.C. § 271(e)(2).